Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 376 AL 390

Prospects of Saffron and its Derivatives in Alzheimer's Disease

Zandi N, Pazoki B, Momeni Roudsari N, Lashgari NA, Jamshidi V, Momtaz S, Abdolghaffari AH, Akhondzadeh S.

Arch Iran Med. 2021 Mar 1;24(3):233-252. doi: 10.34172/aim.2021.35.

Atypical antipsychotics in the treatment of psychotic symptoms in Alzheimer's disease: a systematic review

Vinaşi R, Buciuta A, Coman HG.

Int Clin Psychopharmacol. 2021 Jul 1;36(4):169-180. doi: 10.1097/YIC.0000000000000358.

The Effects of Long-term Medication Use in Alzheimer Disease

Karceski S.

Neurology. 2021 Apr 27;96(17):e2247-e2250. doi: 10.1212/WNL.0000000000011843.

Interventional Study to Evaluate the Clinical Effects and Safety of the Nutraceutical Compound BrainUp-10® in a Cohort of Patients with Alzheimer's Disease: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Guzman-Martinez L, Farías GA, Tapia JP, Sánchez MP, Fuentes P, Gloger S, Maccioni RB.

J Alzheimers Dis. 2021;81(3):1231-1241. doi: 10.3233/JAD-201501.

Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends

Dhage PA, Sharbidre AA, Dakua SP, Balakrishnan S.

Biomed Pharmacother. 2021 Jul;139:111634. doi: 10.1016/j.biopha.2021.111634. Epub 2021 May 6.

Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial

Hannestad J, Duclos T, Chao W, Koborsi K, Klutzaritz V, Beck B, Patel AK, Scott J, Thein SG, Cummings JL, Kay G, Braithwaite S, Nikolich K.

J Alzheimers Dis. 2021;81(4):1649-1662. doi: 10.3233/JAD-210011.

Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer's disease lead to depression?

Mitić M, Lazarević-Pašti T.

Expert Opin Drug Metab Toxicol. 2021 Jul;17(7):841-856. doi: 10.1080/17425255.2021.1931681. Epub 2021 Jun 10.

New IDEAS Amyloid Imaging 2021 Study: Running in Place with Ineffective Anti-Amyloid Treatments for Alzheimer's Disease Patients

Barrio JR, Whitehouse P, Alavi A, Høilund-Carlsen PF.

J Alzheimers Dis. 2021;82(2):461-462. doi: 10.3233/JAD-210383.

The need to show minimum clinically important differences in Alzheimer's disease trials

Liu KY, Schneider LS, Howard R.

Lancet Psychiatry. 2021 Nov;8(11):1013-1016. doi: 10.1016/S2215-0366(21)00197-8. Epub 2021 Jun 1.

Neurodegenerative Diseases: A Multidisciplinary Approach

Marcos-Rabal P, González-Fuentes J, Castro-Vázquez L, Lozano MV, Rodríguez-Robledo V, Santander-Ortega MJ, Selva-Clemente J, Villaseca-González N, Del Mar Arroyo-Jiménez M.

Curr Pharm Des. 2021 Oct 5;27(30):3305-3336. doi: 10.2174/1381612827666210608152745.

Older Adults with Alzheimer's Disease: The Need to Improve Systems of Care

Hung WW.

Clin Ther. 2021 Jun;43(6):920-921. doi: 10.1016/j.clinthera.2021.05.007. Epub 2021 Jun 6.

Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease

Khavinson VK, Lin'kova NS, Umnov RS.

Bull Exp Biol Med. 2021 May;171(2):190-193. doi: 10.1007/s10517-021-05192-6. Epub 2021 Jun 26.

Quantum dots as a theranostic approach in Alzheimer's disease: a systematic review

Villalva MD, Agarwal V, Ulanova M, Sachdev PS, Braidy N.

Nanomedicine (Lond). 2021 Aug;16(18):1595-1611. doi: 10.2217/nnm-2021-0104. Epub 2021 Jun 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias